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Summary
Mediterranean spotted fever (MSF) is a tick-borne disease caused by Rickettsia conorii. It
is characterized by the symptomatologic triad of fever, exanthema and «tache noire» – the
typical eschar at the site of the tick bite. Oral or parenteral administration of tetracyclines
or chloramphenicol represent the standard treatment; however, both these drugs may cause
significant adverse effects in children. Recent studies indicate that oral clarithromycin and
azithromycin may represent an acceptable alternative for the treatment of children with
MSF. There are no data to indicate that antimicrobial prophylaxis is beneficial for tick-bit-
ten patients to prevent MSF. However, in the presence of a lesion ascribed to «tache noire»,
antibiotic treatment should be started even in the absence of fever or exanthema.
Riassunto
La Febbre bottonosa del Mediterraneo (FBM) è una rickettsiosi trasmessa da zecche
causata da Rickettsia conorii. La malattia è caratterizzata dalla triade sintomatologica:
febbre, esantema e «tache noire», la tipica escara necrotica che compare nella sede della
puntura della zecca. Il trattamento ha previsto finora l’utilizzo per via orale o parenterale
del cloramfenicolo o delle tetracicline, farmaci che possono causare gravi effetti col-
laterali nel bambino. Studi recenti indicano che l’azitromicina e la claritromicina som-
ministrati per via orale possono rappresentare una valida alternativa nel trattamento
della FBM in età pediatrica. Non ci sono dati che indicano che la chemioprofilassi nei
soggetti punti dalla zecca è utile per prevenire la FBM. Comunque in presenza di una
lesione ascrivibile alla «tache noire» la terapia antibiotica dovrebbe essere iniziata anche
in assenza di febbre ed esantema.
Introduction
Mediterranean spotted fever (MSF) (or Boutonneuse fever) is a tick-borne
disease caused by Rickettsia conorii. In the Mediterranean area this organism
is transmitted to humans by the brown dog tick Rhipicephalus sanguineus (in
the nymph, larvae or adult stage), generally considered to be the most com-
mon tick present in this region 1-3 (Fig. 1).
However, R. conorii has been documented in at least 25 other species of tick
of the Ixodidae family. Some of these parasites are small mammals and could
play a role in ensuring the wild cycle of this rickettsia 4. Ticks are the only
vector and the main host of R. conorii, being rickettsiae transmitted vertical-
ly and transovarially from females via the eggs to the larvae of the next gen-
eration 3-6 (Fig. 2).
Dogs can be infected by R. conorii, but clinical signs of the disease have not
been reported 7. By acting as natural hosts for R. sanguineus, dogs signifi-
cantly increase contact between these species and humans, thereby increasing
the risk of transmission 8.
Interestingly, the number of cases of MSF in Italy and
elsewhere appears to have increased over the past 20
years 9-10 (Fig. 3). Sporadic cases as a result of tourism
have been diagnosed in other countries 11 and in North
America, where MSF is the most frequently imported
rickettsiosis 12. Many factors have been called into play
to explain the increase in the number of cases 4 (Tab. I).
In Italy the regions with the highest incidence are Sici-
ly and Sardinia; in 1998, an average of 8.8 cases oc-
curred every 100,000 people in Sicily, compared with
the national average of 1.6 cases per 100,000 people.
The seasonal peak of the disease (June through Sep-
tember) occurs during maximal activity of immature
stage ticks 13 14 (Fig. 4).
Clinical features
The infecting tick bite is painless, and the tick is usual-
ly unnoticed, especially in the case of smaller larvae or
nymphs . When not engorged, at these stages ticks are
smaller than a pinhead. A history of tick bite is an im-
portant finding but is often absent. In several cases of
MSF, ticks were found at the site of a bite on patients
who had been ill for several days. The patients simply
had not noticed the presence of ticks, which must have
been attached for more than 10 days, since the incuba-
tion period for the disease is usually 7 days 15 16.
MSF is characterized by a symptomatologic triad:
fever, exanthema and «tache noire». The onset of fever
is generally sudden, and in typical cases body temper-
ature is > 39 °C. Usually exanthema ensues 2-3 days
after the fever and rarely later than the 5th day. Exan-
thema is initially macular and sparse and generally ap-
pears first on the wrists and ankles, spreading rapidly to
the palms and soles (Fig. 5); it subsequently becomes
maculopapular and extends to the trunk and less fre-
quently to the face, often turning red-purple in color. In
some patients only a few lesions resembling mosquito
bites may be present, in others the exanthema may be
petechial or purpuric and rarely papulovesicular 1.
While papulovesicular exanthema seen in MSF cases
may be explained by variant strains of R. conorii or, al-
ternatively, by an unusual host response to the infec-
tion, it cannot be excluded that it might be caused by
other Rickettsia species, and serologically “positive”
results may be due to cross-reactions. For example, R.
akari, the agent of rickettsialpox, is a possible cause of
papulo-vesicular exanthema. While this organism has
never been isolated in Italy, it has recently been report-
ed in Croatia 15.
The «tache noire», the typical eschar at the site of the
tick bite, is present in about 70% of cases (Fig. 6). It is
generally – but not necessarily – a single lesion (Fig.
7); the most common localizations of tache noire seen
in a large series are shown in Figure 8. On the scalp the
«tache noire» is often surrounded by an area of alope-
cia (Fig. 9). Lymph nodes draining the skin site of the
tick bite can be tender and slightly painful on palpation.
Arthralgia and/or myalgia generally involve the joints
and the muscles of the lower limbs, but only rarely do
they restrict mobility. Arthritis generally affects a sin-
gle joint of the lower limb with moderate signs of in-
flammation (slight tenderness, erythema, and swelling
and pain on motion). Arthralgia is more severe in
adults. Headache is a rare complaint in children, while
it is a typical symptom of the disease in adults 2.
Non-exanthematic forms can occur, and, in these cases,
the only signs of infection can be the presence of lym-
phadenopathy and/or tache noire and/or fever 1. Non-
exanthematic forms may at least in part explain the dis-
crepancy between the high prevalence of seropositivity
and the prevalence of the disease documented in some
studies 10.
In the Western Hemisphere, the Rocky Mountain spot-
ted fever (RMSF), caused by Rickettsia rickettsii, can be
a severe disease, but MSF is generally milder. Histori-
cal studies have shown that MSF can lead to 10-14 days
of fever if untreated, and that it is rarely fatal in children
2
. Severe forms of the disease have been reported in 6%
of patients, especially adults with one of the following
conditions: diabetes, cardiac disease, chronic alco-
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Fig. 1. Rhipicephalus sanguineus on vegetation waiting for pas-
sing hosts, with its front legs held out in an ambush strategy.
Ixodid ticks (or «hard ticks», thus called for their sclerotized dor-
sal plate) spend > 90% of their life unattached from the host.
They are usually seasonally active, seeking their hosts when en-
vironmental conditions are most suitable. They are highly re-
sponsive to stimuli that indicate the presence of hosts. These in-
clude chemical stimuli (such as CO2, NH3) phenols, humidity, aro-
matic chemicals, airborne vibrations and body temperature as-
sociated with warm-blooded animals. In their ambush strategy,
ticks climb up vegetation and wait for passing hosts, with their
front legs held out in the same manner as are insect antennae 3.
Many ticks lack eyes, and even when eyes are present, they are
unlikely to enable a detailed perception of the environment.
However, ticks have a variety of peripheral sensory organs. The-
se include hair-like structures on the body, legs, and mouth-
parts, and a sensory complex located on the dorsal surface of
the tarsus of leg I, which contains a cluster of olfactory and gu-
statory receptors (Haller’s organ). These sensory organs are
clearly important in enabling ticks to locate their hosts 3.
holism, glucose-6-phosphate dehydrogenase deficiency,
end stage kidney disease. Mortality rate may reach
2.5%. Patients with malignant forms have a petechial
rash and neurological, renal, and cardiac problems; this
is especially the case in elderly people 16.
Israeli spotted fever caused by R. israeli is more severe
than MSF. It is characterized by more frequent purpuric
rash, thrombocytopenia, hyponatriemia and systemic
complications, such as pneumonia, nephritis, en-
cephalopathy, and occasional fatalities also in children;
unlike MSF there is no «tache noire» 16. Initially, the
distribution of Israeli spotted fever rickettsia appeared
to be restricted to Israel, but more recently the organ-
ism has also been isolated from patients with MSF in
Portugal 17 and from R. sanguineus ticks collected in
1990 in western Sicily 18.
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Fig. 2. Life cycle of Rhipicephalus sanguineus and Rickettsia conorii.
The life cycle of ixodid ticks is a 3-host one, with a single host chosen at each feeding stage of the tick (larva, nymph, and adult). At each
developmental stage the tick searches for a host, attaches to it, and then feeds over a period of several days. Once replete, the tick dro-
ps off the host and looks for a place where it can digest its blood meal. The tick can then moult to the next stage, or enter diapause, a
condition in which metabolism is reduced and development delayed 3.
The life cycle is usually completed in 2-3 years, but may take from 6 months to 6 years, depending on environmental conditions, inclu-
ding temperature, relative humidity, and photoperiod. Mating generally occurs on the host. Gravid females lay thousands of eggs on the
grass (4-6 weeks). Eggs hatch into larvae (4-6 weeks); next, engorged larvae shelter in grass and moult into nymphs (4-6 weeks); finally,
engorged nymphs shelter in the grass and moult into adults (10-20 weeks) 3. The transmission cycle of R. conorii is shown in the dashed
circle. Infection with R. conorii can induce in R. sanguineus mortality, severe malformations and alterations in the feeding behavior (de-
layed engorgement) 6.
The adult stage of the brown dog tick Rhipicephalus sanguineus is very host-specific; it rarely bites humans 13. Larval and nymph stages
are usually less specific in their choice of the host and bite humans more often than adult ticks do.
Before feeding, a tick may wander around on its host for several hours. It inserts only its hypostome into the skin, inoculating the host
with various substances produced by the salivary glands, creating a feeding pool. During the first 24-36 h of attachment, there is little or
no ingestion of blood.
The salivary secretions produced by ixodid ticks include a kind of cement to anchor the mouthparts to the skin of the host; enzymes; va-
sodilators; and anti-inflammatory, antihemostatic, and immunosuppressive substances. These facilitate successful blood feeding, and an
anesthetic in the saliva makes the bite of Ixodid ticks usually painless 3.
The feeding period of ixodid ticks is quite long, requiring 2-15 days for a complete blood meal to be ingested; the length of the ingestion
period depends on different factors, such as the species of tick, the feeding stage, the type of host, and attachment site. After an initial
slow feeding phase (3-4 days) a period of rapid engorgement follows (1-3 days) during which the body weight of ticks, particularly fema-
les, may increase up to 120-fold. While feeding, blood sucking and salivation alternate and, at the end of the rapid engorgement phase,
regurgitation occurs frequently, thus increasing the transmission of infectious agents.
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Fig. 4. Monthly distribution of 868 cases of MSF 14.
Fig. 3. Annual incidence of MSF cases (clinically ascertained) in Italy and Sicily (official reporting system, Italian Ministry of Health).
Laboratory findings
The main laboratory findings are a slight increase in
transaminases and mild thrombocytopenia. Recently
we have demonstrated that serum concentrations of tu-
mor necrosis factor alpha and interferon gamma are
lower in children with non-exanthematic or mild exan-
thematic forms as compared to children with typical
exanthema 19. These two cytokines play an important
role in the defense against R. conorii, and are associat-
ed with the vasculitis that characterizes MSF. Milder
forms could be due to a reduced activation of the im-
mune system, resulting in a minimum albeit sufficient
dose of the two cytokines to be able to destroy R.
conorii and cause only slight tissue damage.
The Weil-Felix test was the first assay used to diagnose
MSF and other rickettsioses. It is based on serological
cross-reactions between sera from patients affected by
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rickettsial infection and somatic antigens of three Pro-
teus strains: P. vulgaris OX2 (R. conorii), P. vulgaris
OX19 (R. rickettsii), and P. mirabilis OXK (O. tsutsug-
amushi). This test lacks sensitivity and specificity. It
could be used only as first line testing in rudimentary
hospital laboratories. Today, the most commonly used
serological test is the IFAT 16. However, in our experi-
ence, only titers < 1:80 of specific IgM are generally
present at the onset of the disease; we have seen such
low levels in other systemic diseases as well (unpub-
lished data). Confirmation of the diagnosis of MSF
thus requires documentation of a seroconversion 3-4
weeks after the onset of symptoms 1.
Recently, a shell vial system has been devised that al-
lows detections of rickettsiae in blood within just 48 ±
72 h 20; subsequently, an immunomagnetic procedure has
been developed for the isolation of circulating endothe-
lial cells in blood, that allows the confirmation of MSF
in about 3.5 h 21. A sensitive and specific PCR test based
on sequences of the 17-kD protein gene of R. conorii has
been developed by Leitner et al. 22. However, these pro-
cedures are restricted to specialized laboratories.
Because of the frequent lack of several classical clini-
cal and laboratory findings, a diagnosis score has been
proposed to facilitate the diagnosis of this disease 23.
(Tab. II).
Therapy
Members of the genus Rickettsia are obligate intracel-
lular bacteria, and the main feature of MSF is general-
ized vasculitis with localization of R. conorii in the cy-
toplasm of endothelial cells 16. Effective intracellular
concentrations of antimicrobials are therefore consid-
ered the «sine qua non» for successful treatment for
this disease.
Until now there has not been a gold-standard therapy
for children with rickettsial diseases. Standard treat-
ment for MSF was the oral or parenteral administration
of tetracyclines or chloramphenicol, drugs that achieve
good membrane penetration and concentrate within the
cytoplasm. However, both drugs can have significant
adverse effects in children. Tetracyclines can cause
staining of the teeth and bone toxicity 24; chloram-
phenicol can cause gray-baby syndrome, aplastic ane-
mia, and acute hemolytic anemia in patients with the
Mediterranean form of glucose-6-phosphate dehydro-
genase (G6PD) deficiency 25-27. Nevertheless, doxycy-
cline is the treatment of choice for children aged < 8
years with RMSF 28.
Until 2000 chloramphenicol was considered  «the less-
er of two evils», and this antibiotic was used as the
drug of choice for the treatment of MSF in children 1.
The macrolides clarithromycin, azithromycin, rox-
ithromycin, and josamycin, which are often used to
treat infections in children, lack such adverse effects.
The few studies that have evaluated the «in vitro» ac-
tivity of these drugs against R. conorii 29-31 suggest that
clarithromycin and azithromycin may be of interest for
their better pharmacological and pharmacokinetic
properties compared to other macrolides 30. Recently,
14 hydroxy-clarithromycin, the primary metabolite of
clarithromycin, has been demonstrated to attain serum
concentrations 3 times greater than its MIC 29 30. More-
over, the combination of clarithromycin and its 14-hy-
droxy metabolite have been shown to produce MICs
and postantibiotic effects greater than those associated
with the use of clarithromycin alone 29. Since
azithromycin achieves high intracellular concentrations
and has a particularly long intracellular half-life, it may
therefore be possible to: 1) reduce doses; 2) prolong the
interval between each administration; and 3) shorten
Tab. I. Factors alleged to explain the increase in MSF 4.
• Increased number of ticks
Climatic changes, i.e. «Global warming»
Lack of rainfalls
Forbidden use of D.D.T.
Fauna changes
Decreased number of tick predators
Increase in wild rodents and stray dogs
• Increased contact with ticks
Urban expansion towards rural parts of endemic areas
Increased leisure activities (camping)
Increased number of pet-dogs
Fig. 5. Typical exanthema on the palms.
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the duration of administration, compared to other drug
treatments 32. Given this background information, we
undertook an RCT comparing the efficacy and safety of
clarithromycin versus chloramphenicol to treat MSF in
children, and found that clarithromycin was signifi-
cantly more effective than chloramphenicol 33 (Fig. 10).
Subsequently we conducted another RCT to compare
the safety and efficacy of clarithromycin versus those
of azithromycin. We were unable to demonstrate sig-
nificant differences between the two treatment groups
in terms of time to defervescence and disappearance of
other symptoms 34.
Other three RCTs have been performed to compare
macrolides for the treatment of MSF in children 35-37. In
all these studies, the drugs were administered orally, and
the clinical response to the different antibiotic treat-
ments was evaluated on the basis of the pattern of body
temperature and the improvement of the clinical signs
and symptoms of the disease. Only the study 33 that
compared the efficacy of clarithromycin versus chlo-
ramphenicol obtained better (statistically significant)
results for the clarithromycin group. On the other hand,
only one of the other studies 36 showed that tetracycline
hydrochloride is better than erythromycin stearate.
However, erythromycin displayed an «in vitro» activity
against R. conorii that was not as potent as that of new-
er macrolides, such as clarithromycin 29 30 38-41.
In conclusion, clarithromycin and azithromycin could be
acceptable therapeutic alternatives to chloramphenicol
Fig. 6. Clinical findings in 645 pediatric cases of MSF 1.
Fig. 7. Typical tache noire on the abdomen.
and tetracyclines for children aged < 8 years with MSF.
Since azithromycin has a long half-life, it offers the ad-
vantages of administration in a single daily dose and a
shorter duration of therapy, which could increase com-
pliance in children. Further evaluation of macrolides in
patients with severe symptoms or more severe illness
should be undertaken. Because these drugs have not
been tested as treatment for RMSF or other rickettsioses,
their use for these diseases is not recommended.
Although macrolides should not be used to treat MSF
in adults until RCTs have demonstrated at least the
same efficacy of chloramphenicol or tetracyclines,
their use could be recommended during pregnancy.
As far as children are concerned, we think that until
large studies in open populations will confirm the re-
sults of the RCTs performed 33 34, clarithromycin (7.5
mg/kg b.i.d.) and azithromycin (10 mg/kg once a day)
should be administered until at least 48 hours after de-
fervescence. In case of neurological signs, tetracyclines
(minocycline or doxycycline) or chloramphenicol
should be given at any age.
What to do in case of a tick bite
The tick should be removed using rounded forceps and
– should immature ticks be found – with the help of a
magnifying glass. The mouthparts of the ticks must be
grasped as close to the skin as possible, and the tick
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Fig. 8. Localization of tache noire in 645 pediatric cases of MSF 1.
Fig. 9. Alopecia surrounding a large tache noire on the scalp.
must then be pulled upward, perpendicular to the sur-
face, with a steady pressure 3.
After the tick has been removed, the bite site should be
disinfected thoroughly. It is not advisable to remove
ticks by using the fingers instead of forceps, or try and
kill them in situ with lighted cigarettes, petroleum jel-
ly, or suntan oil: these methods, in fact, may increase
the risk of regurgitation by the tick and, consequently,
the transmission of infectious agents 3.
It should be kept in mind that only about 10% of R. san-
guineus are infected by R. conorii in areas in which
MSF is endemic; in addition, the risk of transmission of
a bacterial disease by a tick increases with the duration
of attachment and generally requires 24-48 h. The de-
gree of tick engorgement or the time from tick expo-
sure to its detection may help define the likely duration
of the attachment and the risk of disease transmission.
There are no data to indicate that antimicrobial pro-
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Fig. 10. Time to defervescence in children treated with chloramphenicol or clarithromycin 33.
Tab. II. Diagnostic scoring system for Mediterranean spotted fever, as described by Raoult et al. 23.
Diagnostic criterion Points
Epidemiologic criteria
Living or recent travel in endemic area 2
Onset between May and September 2
Contact with dog ticks 2
Clinical criteria
Fever above 39 °C 5
«Tache noire» 5
Maculopapular or purpuric eruption 5
Two of the three clinical criteria 3
All three clinical criteria 5
Non specific biological criteria
Platelet count < 150 x 109/liter 1
Liver enzymes (AST or ALT) > 50 IU/liter 1
Bacteriological criteria
Detection of R. conorii in skin biopsy by using immunofluorescence assay 25
Isolation of R. conorii from blood 25
Serological criteria (immunofluorescence)
Single serum sample with total Ig of ≥ 1:128 5
Single serum sample with IgG of ≥ 1:128 and IgM of ≥ 1:64 10
Two serum samples with fourfold titer elevation within 2 weeks 20
Note. A total of > 25 points is consistent with a presumptive diagnosis of Mediterranean spotted fever.
phylaxis is beneficial for tick-bitten patients to prevent
MSF or other rickettsioses, Lyme disease and tu-
laremia 3. However, patients should be alerted on the
signs and symptoms of tick transmitted diseases and
seek medical help  in case of contact.
In the presence of a lesion ascribed to «tache noire» we
recommend to start antibiotic treatment even if fever or
exanthema are not present.
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Tab. III. Summary of the findings of 5 randomized clinical trials of macrolide treatment for Mediterranean spotted fever in children 34.
Reference Drugs and regimens studied No. of Outcome
patients
35 Erythromycin stearate, 10 days 81 more rapid disappearance
(12.5 mg/kg q.i.d) vs. of fever and symptoms
tetracycline hydrochloride, in the group treated with
10 days (10 mg/kg q.i.d.) tetracycline
36 Azithromycin, 3 days 30 no statistically significant
(10 mg/kg once a day) vs. differences in time to
doxycycline, 5 days defervescence
(5 mg/kg once a day)
37 Doxycycline, 1 day 32 no statistically significant
(2.5 mg/kg b.i.d.) vs. josamycin, differences in time
5 days (25 mg/kg b.i.d.) to defervescence
33 Clarithromycin, 7 days 46 more rapid disappearance
(7.5 mg/kg b.i.d.) vs. of fever in the group
chloramphenicol, 7 days treated with clarithromycin
(12.5 mg/kg q.i.d.)
34 Azithromycin, 3 days 87 no statistically significant
(10 mg/kg once a day) vs. differences in time
clarithromycin, 7 days to defervescence
(7.5 mg/kg b.i.d.)
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